ALGN vs BBIO
Align Technology vs BridgeBio Pharma, Inc. — AI-powered side-by-side comparison
ALGN
Align Technology
73
Buy
VS
BBIO
BridgeBio Pharma, Inc.
65
Insufficient Data
| Metric | ALGN | BBIO |
|---|
| AI Score |
73
|
65
|
| Price |
$172.86
|
$83.71
|
| P/E Ratio |
30.03×
|
-23.38×
|
| ROE |
10.1%
|
35.1%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
66.5%
|
93.1%
|
| Debt / Equity |
0.03×
|
-0.99×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
55.1
|
56.9
|
| Beta |
1.653
|
0.983
|
| Expected Upside |
+7.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALGN versus BBIO.
ALGN leads by 8 points.
ALGN scores 73/100 (Buy) versus BBIO at 65/100 (Insufficient Data).
ALGN Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
BBIO Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical